Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for active psoriatic arthritis:
- Bimekizumab for treating active psoriatic arthritis (2023) NICE technology appraisal guidance 916
- Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (2022) NICE technology appraisal guidance 815
- Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (2022) NICE technology appraisal guidance 803
- Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (2022) NICE technology appraisal guidance 768
- Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (2018) NICE technology appraisal guidance 543
- Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (2018) NICE technology appraisal guidance 537
- Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (2017) NICE technology appraisal guidance 445
- Apremilast for treating active psoriatic arthritis (2017) NICE technology appraisal guidance 433
- Ustekinumab for treating active psoriatic arthritis (2015) NICE technology appraisal guidance 340
- Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (2010) NICE technology appraisal guidance 199
This page was last updated: